Abstract

**Background:** Depression is a risk factor for worse HIV outcomes in persons living with HIV/AIDS, including engagement-in-care, HIV medication adherence, and retention-in-care. Depression has a prevalence of more than three times as high as in the general population. Despite this, there are few randomized studies of antidepressants in HIV-infected Africans, including those with opportunistic infections.

**Methods:** We enrolled 460 HIV-infected Ugandans with cryptococcal meningitis into a randomized clinical trial of adjunctive sertraline vs placebo (2015-2017). We defined depression using the Center for Epidemiologic Studies Depression Scale (CES-D) score of >15, and
severe depression as >26 at one and three months after meningitis diagnosis and initiation of treatment. We evaluated the relationship between sertraline and depression, as well as associations with persistent depression, at three months.

**Results:** At one- and three-months post meningitis diagnosis, 62% (108/174) and 44% (74/169) of all subjects had depression (CES>15), respectively. At three months, sertraline-treated subjects had consistent risk for depression as placebo-treated subjects but were significantly less likely to have severe depression (CES>26) (OR 0.335; 95%CI, 0.130-0.865). Of those with depression at one month, sertraline-treated subjects were less likely than placebo-treated subjects to be depressed at three months (p=0.05). Sertraline was the only factor we found significant in predicting persistent depression at three months among those with depression at one month.

**Conclusions:** Depression is highly prevalent in HIV-infected persons who have survived cryptococcal meningitis. We found that sertraline is associated with a modest reduction in depression in those with depression at baseline and a significant decrease in severe depression.

**Keywords**
Depression, HIV, sertraline, Antidepressive Agents, Depressive Disorder, Treatment-Resistant, biomarkers

---

**Grant information:** This work was supported by the Wellcome Trust through a Clinical PhD Fellowship to FVC [210772] and through the Joint Global Health Trials scheme jointly funded by the UK Medical Research Council, UK Department for International Development and the Wellcome Trust [M007413/1]. This research was also supported by the National Institute of Neurologic Diseases and Stroke, the Fogarty International Center [R01NS086312, R25TW009345], the National Institute of Allergy and Infectious Diseases [T32AI055433], the National Institute of Mental Health [K23MH121220], and Grand Challenges Canada [54-0296-01].

**Copyright:** © 2022 Lofgren SM et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Lofgren SM, Velamakanni SS, Hullsiek K et al. A secondary analysis of depression outcomes from a randomized controlled trial of adjunctive sertraline for HIV-associated cryptococcal meningitis [version 2; peer review: 2 approved with reservations] Wellcome Open Research 2022, 6:45 https://doi.org/10.12688/wellcomeopenres.16363.2

**First published:** 26 Feb 2021, 6:45 https://doi.org/10.12688/wellcomeopenres.16363.1
Amendments from Version 1

Our reviewers were concerned that we did not have it in the proper context for an analysis of depression from a study done with sertraline as an antifungal. As such, we changed the title from "The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis" to "A secondary analysis of depression outcomes from a randomized controlled trial of adjunctive sertraline for HIV-associated cryptococcal meningitis." In the Abstract, we made the HIV effects of depression more specific. In the Introduction, we added a paragraph about the sequela of cryptococcal meningitis. In the Methods, we added details about sertraline dosing in this study. We did some grammatical polishing throughout. In the Discussion, we added a paragraph about sertraline dosing in the study compared to the usual dosing for depression. We added context to depression treatment in Africa. Finally, we moved a paragraph about antidepressant therapy among people with cryptococcal meningitis to the end of the Discussion.

Any further responses from the reviewers can be found at the end of the article.

Introduction

In persons living with HIV/AIDS, the prevalence of depression is up to three times more common than in the general population^1^, making depression one of the most common neuropsychiatric complications in these individuals. The underdiagnosis of major depression in people with HIV undoubtedly contributes negatively to individuals’ overall well-being. People diagnosed with depression and HIV infection often have poorer clinical and HIV outcomes than those diagnosed with HIV infection without depression^2^,3^. Treatment for depression in people living with HIV/AIDS utilizes the same mainstays: antidepressant medication and talk therapy^4^,5^,. However, there is surprisingly little data on the efficacy of depression therapies in individuals with HIV^6^,7^,8^.

Additionally, people with meningitis are known to have long-term sequela such as deafness^9^,10^,11^,12^,. However, there is a paucity of data about the prevalence of psychiatric consequences among people following meningitis, much less the treatment of said disease^13^,14^. Cryptococcal meningitis is a complex condition as people generally have advanced immunosuppression such as advanced HIV to be susceptible. Given cryptococcal meningitis is highly prevalent at 220,000 cases a year, a month, more information is needed about the long-term consequences of survivors.

Here we present data on the rates of depression in participants in a cryptococcal meningitis trial, the effects of sertraline on said depression, and risk factors for persistent depression in this cohort. This work is a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial that investigated the utility of adjunctive sertraline as a putative antifungal medicine among persons with AIDS and cryptococcal meningitis. Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis (ASTRO-CM)^16^, The trial assessed depression via the Center for Epidemiologic Studies Depression Scale (CES-D) as a secondary endpoint. We sought to evaluate the effect of sertraline on the prevalence and severity of depression in cryptococcal meningitis survivors from the randomized trial. We also assessed risk factors for and the prevalence of depression among pooled prospective cohorts from 2010–2017, including ASTRO-CM, among Ugandans surviving cryptococcal meningitis.

Methods

For this paper, we used data from the ASTRO-CM randomized trial^16^, In ASTRO-CM, we prospectively consented 460 HIV-infected adults who tested positive for cerebrospinal fluid (CSF) cryptococcal antigen at Mulago National Referral Hospital in Kampala, Uganda from March 2015 to May 2017. All participants received intravenous amphotericin B deoxycholate (0.7–1.0 mg/kg/day) with oral fluconazole 800mg/day. Participants were treated for meningitis as an inpatient for at least one week. They were randomized to receive either adjunctive sertraline or placebo; 229 participants started with 400mg/day of sertraline, while 231 received the placebo^16^. Sertraline at 400mg/day was continued for 2 weeks, decreased to 200 mg/day for 12 weeks, and then tapered off over 3 weeks. The dosing was for antifungal treatment and double the maximum dose for depression. Depression scores were evaluated at one and three months using the CES-D scale, a self-reported questionnaire comprised of 20 items representing overall mood and feelings. Given how ill participants are with cryptococcal meningitis, they were not screened for depression as an inpatient or otherwise prior to their one-month outpatient visit.

Therefore, we defined depression as a CES-D score of >15 on a 0 to 60-point total scale^14^,17^,18^, Mulago National Referral Hospital (MREC 429) and the University of Minnesota Institutional Review Boards (1304M31361) approved the protocol. All participants or their surrogates provided written informed consent.

We compared subjects with depression (CES-D scores >15) to subjects without depression (CES-D score 0–15) on demographic factors, including gender and age, clinical characteristics, such as viral load, fungal burden, antiretroviral medications, mental status based on Glasgow Coma Scale, and persistent depression. We compared continuous variables using Mann-Whitney U and categorical variables using Chi-square. We repeated the analysis in the sub-group of subjects with severe depression using the CES-D cutoff ≥26^16^. We further examined the effect of sertraline versus placebo within the ASTRO-CM randomized trial alone (n=460) regardless of depression status at one month. Finally, we evaluated the data as might be done in an antidepressant drug trial looking at those depressed at baseline (one month) and the change in CESD score, response rate, and remission rates.

We next looked at demographic associations with persistent depression at three months. We first evaluated this in the ASTRO-CM randomized trial alone, followed by a sensitivity analysis for baseline associations of persistent depression. In this sensitivity analysis, we included two other cohorts of cryptococcal meningitis survivors, which also evaluated participants for clinical depression. One of these cohorts included 172 subjects enrolled as a part of the ASTRO-CM
pilot phase II trial. In this pilot study, participants received varying doses of sertraline (100 mg to 400 mg daily) for the first two weeks (n=172), followed by 200 mg sertraline daily until 3 months when it was subsequently tapered\(^2\). The second cohort, the Cryptococcal Optimal Antiretroviral Therapy Timing (COAT) trial, enrolled 177 subjects and assessed early versus deferred initiation of HIV therapy; participants did not receive sertraline in this cohort\(^3\). Finally, we calculated odds ratios to evaluate for risk of depression. Both the analysis and graphing were performed using Microsoft Excel version 16 (Redmond, WA) and IBM SPSS Statistics version 26 (Armonk, NY).

**Results**

We enrolled 460 persons with a first episode of cryptococcal meningitis into the ASTRO-CM sertraline randomized trial. As previously reported, the median age of the enrolled participants was 35 years\(^1\). The median CD4 count was 15 cells/mm\(^3\), and 41% of the enrolled subjects were women. Baseline characteristics are shown in Table 1\(^2\). There were no significant differences at baseline by randomized groups. Overall, 273 (59%) survived more than a month, and 234 (51%) survived more than 3 months.

**Differences between those screened and unscreened for depression**

We selected those who survived for one month and compared those who were screened for depression and those not screened. Overall, 273 (59%) had survived >1 month, and 234 (51%) survived through >3 months. Of subjects who survived one month, 174 (64%) had depression screening performed at one month and 169 (72%) at three months. Those in ASTRO-CM not screened for depression at three months, but were still alive, had higher mortality (p<0.001), a higher CSF opening pressure >200 mmH\(2\)O (p=0.024), and had a higher depression score at one month (p=0.025) compared to those screened for depression at three months. These findings suggest that the reason for not screening for depression was illness-related.

---

**Table 1.** Baseline characteristics in randomized Adjunctive Sertraline for the Treatment of HIV Associated Cryptococcal Meningitis (ASTRO-CM) Trial.

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N=231) Median (IQR) or N(%)</th>
<th>Sertraline (N=229) Median (IQR) or N(%)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>35 (30-41)</td>
<td>35 (29-40)</td>
<td>0.234</td>
</tr>
<tr>
<td>Women</td>
<td>37.7%</td>
<td>97 (42.4%)</td>
<td>0.304</td>
</tr>
<tr>
<td>CD4 cell count, cells/mm(^3)</td>
<td>13 (6-41)</td>
<td>17 (7-47)</td>
<td>0.362</td>
</tr>
<tr>
<td>Receiving ART</td>
<td>48.1%</td>
<td>48.9%</td>
<td>0.854</td>
</tr>
<tr>
<td><strong>Baseline CSF Analysis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening pressure, mm H(2)O</td>
<td>270 (180-410)</td>
<td>248 (170-380)</td>
<td>0.172</td>
</tr>
<tr>
<td>Opening pressure &gt;200 mm H(2)O</td>
<td>68.5%</td>
<td>60.7%</td>
<td>0.100</td>
</tr>
<tr>
<td>Cryptococcal culture, log(_{10}) CFU/mL</td>
<td>4.82 (3.63-5.55)</td>
<td>4.78 (3.56-5.62)</td>
<td>0.946</td>
</tr>
<tr>
<td>Sterile culture</td>
<td>6.6%</td>
<td>11.0%</td>
<td>0.098</td>
</tr>
<tr>
<td>CSF white-cell count &gt;5 cells/mm(^3)</td>
<td>66.2%</td>
<td>58.4%</td>
<td>0.088</td>
</tr>
<tr>
<td>CSF protein, mg/dL</td>
<td>42 (22-100)</td>
<td>47 (23-106)</td>
<td>0.576</td>
</tr>
<tr>
<td>Number of lumbar punctures</td>
<td>4 (2-6)</td>
<td>4 (2-6)</td>
<td>0.858</td>
</tr>
<tr>
<td>2(^{nd}) lumbar puncture opening pressure, mmH(2)O**</td>
<td>260 (140-400)</td>
<td>260 (180-400)</td>
<td>0.859</td>
</tr>
<tr>
<td>Day 14 CSF opening pressure, mmH(2)O</td>
<td>200 (130-300)</td>
<td>200 (150-300)</td>
<td>0.539</td>
</tr>
</tbody>
</table>

*P-values from continuous variables calculated with Mann-Whitney U, p-values from categorical variables calculated with Pearson Chi-square (2-sided).

**2\(^{nd}\) LP at day 2–5 and N=199.

IQR= Interquartile Range, ART= Antiretroviral Therapy, CSF= Cerebrospinal Fluid.
Impact of sertraline on depression

We screened 174 participants for depression at one or three months using the CES-D scoring criteria. At one and three months, 62% (108/174) and 44% (74/169) of all subjects had depression. At three months, those receiving sertraline were non-significantly more likely to be depressed compared to those receiving placebo (37% vs. 64%, p=0.091).

We assessed subgroups of those who may have benefited from sertraline. Depression categories were subdivided into no depression (CES-D <16), moderate depression (CESD 16–25), and severe depression (CES-D ≥26). Those receiving sertraline were significantly less likely to have severe depression at three months versus moderate or no depression than those not on sertraline (p=0.030).

In Figure 1, a population pyramid compares the CES-D score based on sertraline or placebo at one and three months. Sertraline had little effect on depression at one month, with no significant differences between groups.

![Population Pyramid Comparing CES-D score by sertraline or placebo at one and three months.](image)

<table>
<thead>
<tr>
<th>Depression Scores</th>
<th>N</th>
<th>Placebo</th>
<th>N</th>
<th>Sertraline</th>
<th>P-value</th>
<th>Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>CES-D 1 month</td>
<td>90</td>
<td>20 (13-28)</td>
<td>84</td>
<td>20 (11-28)</td>
<td>0.960</td>
<td></td>
</tr>
<tr>
<td>Depressed at 1 month</td>
<td>56</td>
<td>62.2%</td>
<td>52</td>
<td>61.9%</td>
<td>0.966</td>
<td>0.995 (0.815-1.009)</td>
</tr>
<tr>
<td>Severe Depression at 1 month</td>
<td>25</td>
<td>27.8%</td>
<td>32</td>
<td>38.1%</td>
<td>0.147</td>
<td>1.371 (0.751-2.503)</td>
</tr>
<tr>
<td>CES-D 3 months</td>
<td>95</td>
<td>15 (7-25)</td>
<td>74</td>
<td>12 (7-19)</td>
<td>0.074</td>
<td></td>
</tr>
<tr>
<td>Depressed at 3 months</td>
<td>47</td>
<td>49.5%</td>
<td>27</td>
<td>36.5%</td>
<td>0.091</td>
<td>0.738 (0.420-1.294)</td>
</tr>
<tr>
<td>Severe Depression at 3 months</td>
<td>23</td>
<td>24.2%</td>
<td>6</td>
<td>8.1%</td>
<td>0.006</td>
<td>0.338 (0.130-0.885)</td>
</tr>
</tbody>
</table>

Numbers are n (%) and median (IQR). P-values by non-parametric Mann Whitney U or by Chi-square.

Figure 1. Population Pyramid Comparing CES-D score by sertraline or placebo at one and three months.
There was a similar percentage of people with depression receiving sertraline compared with placebo (62.2% vs. 61.9%, p=0.966), and more with severe depression (38.1% vs. 27.8% p=0.147). However, by three months, there were lower rates of depression in individuals receiving sertraline versus those receiving placebo (36.5% vs. 49.5%, p=0.091), though not statistically significant. At three months, significantly fewer participants receiving sertraline had severe depression compared with those receiving placebo (8.1% vs. 24.2%, p=0.006).

Outside a clinical trial using sertraline as an antifungal, a patient would typically only be prescribed an anti-depressant as an outpatient. Therefore, we examined those 135 who had depression (CES-D ≥16) at one-month post meningitis diagnosis, which is the time of entering outpatient HIV care. We also evaluated the baseline (one month) to endpoint (three months) change in CES-D score for sertraline versus placebo. We found that the median (IQR) change was 8 (-2.5–19.5) for sertraline versus 5 (-2–12), p=0.095. We also evaluated the response rate of 50% improvement in CES-D score from one to three months. We found that the response rate for sertraline was 50% compared to 33.8% for placebo (p=0.056). As stated above, the percentage of resolved depression was not statistically better for sertraline than placebo (p=0.091).

**Baseline factors associated with persistent depression at three months in ASTRO-CM sertraline randomized control trial**

Factors associated with persistent depression at three months in the randomized ASTRO-CM sertraline trial were evaluated (Table 2). A higher percentage of women (44 (59.5%)) and those with Glasgow coma scale <15 (33 (44.6%)) trended towards being more likely to be depressed (CES-D >15) than men and those with Glasgow coma scale of 15. Depression at one month was not associated with depression at three months (65% vs. 55%, p=0.286).

**Baseline factors associated with persistent depression at three months in combined cohorts**

Factors associated with persistent depression at three months were examined from the combined cohorts of 883 participants (2010–2017) to determine if our findings were generalizable. In the combined cohorts, 66.3% and 38.5% of subjects had depression at one and three months, respectively. Those with depression at three months were less likely to be from Kampala (82.5% vs. 96.2% p<0.001) and were more likely to have a Glasgow Coma Score (GCS) <15 at entry (37.7% vs. 26.5%, p= 0.043). Sertraline was not associated with a difference in depression (41.2% vs. 48.4%, p=0.231) in the combined cohorts.

**Discussion**

This analysis of participants with cryptococcal meningitis reveals that sertraline given regardless of depression status in the ASTRO-CM sertraline randomized trial did not significantly reduce depression. The change in CESD, response rate, and remission rate were not significantly better in sertraline compared to placebo among all comers. Sertraline significantly lowered the prevalence of severe depression in those recovering from cryptococcal meningitis for all-comers. Further, sertraline was associated with significantly less depression at three months in those with depression at one month.

The percentage of participants with depressive symptoms at one month was 67% in ASTRO-CM, which likely represents major depression, acute adjustment disorder, pain, severe illness, and appropriate anxiety. At three months, the percentage of participants with depressive symptoms was 44% in ASTRO-CM. While this still is affected by pain, illness, and other factors, it is likely a better measure of depression symptoms than other causes. For this reason, we based our depression outcomes on three and not one-month outcomes.

The study participants had multiple reasons to have depressive symptoms at one and three months. As the subjects had just survived a critical illness, they were still quite ill with advanced HIV, and many had yet to start or re-start HIV medication. Most participants had not worked for weeks to months, and many had just disclosed their HIV status to their loved ones for the first time. In the open wards of the hospital, the individuals in the study knew other participants who had died and understood better than most, the mortality associated with cryptococcal meningitis. Anecdotally, our staff found that counseling and social support helped participants considerably.

In the combined cohorts, individuals from areas outside of Kampala and those with a GCS<15 were found to have higher rates of depression. This association with location could be due to limited financial resources and the inability to access necessary healthcare in outlying areas. In addition, those with GCS <15 were sicker, which may be associated with more symptoms such as headaches and needing more frequent lumbar punctures. However, there was no variation in the fungal burden between the groups.

Participants who had their CES-D measured in this study were well enough to attend outpatient clinic and answer survey questions. Not only did these participants have lower fungal burdens, but they were also less likely to have altered mental status and had decreased mortality rates. This selection bias of mortality for those screened for depression is a limitation of this study but one true of all studies with critically ill individuals.

The dosage of sertraline used in this study was 400mg/day for two weeks, followed by 200 mg/day for 12 weeks, then tapered off over 3 weeks. The recommended starting dose of sertraline for depression is 50 mg/day with a general maximum recommended dose of 200 mg/day21. Sertraline has been shown to have dose dependence effects, with some studies showing short-term use of 400 mg with good response on depression21. We used 400 mg/day for the treatment of Cryptococcus, not for depressive symptoms8. These patients were monitored as inpatients over at least one week, and sertraline was generally well tolerated. Since the efficacy of sertraline is generally over 4–6 weeks, we would expect some signs of reduced depression at our 4-week timepoint and certainly at 3 months22.
## Table 2. Factors associated with persistent depression at three Months in Randomized Adjunctive Sertraline for the Treatment of HIV Associated Cryptococcal Meningitis (ASTRO-CM) Trial.

<table>
<thead>
<tr>
<th></th>
<th>Depression CES-D ≥16 (N=74) Median (IQR)</th>
<th>No Depression CES-D &lt;16 (N=95) Median (IQR)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CES-D Score at three months</td>
<td>23 (18-30)</td>
<td>8 (4-11)</td>
<td>----</td>
</tr>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>34.5 (29.0-40.0)</td>
<td>35.0 (29.0-38.0)</td>
<td>0.313</td>
</tr>
<tr>
<td>Women</td>
<td>40.5%</td>
<td>28.4%</td>
<td>0.098</td>
</tr>
<tr>
<td><strong>Clinical characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glasgow Coma Scale Score &lt;15</td>
<td>44.6%</td>
<td>31.6%</td>
<td>0.083</td>
</tr>
<tr>
<td>CD4 cell count, cells/mm³</td>
<td>16 (7-51)</td>
<td>19 (8-52)</td>
<td>0.996</td>
</tr>
<tr>
<td>Receiving ART</td>
<td>40.5%</td>
<td>49.5%</td>
<td>0.247</td>
</tr>
<tr>
<td><strong>Baseline CSF Analysis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening pressure, mm H₂O</td>
<td>265 (180-370)</td>
<td>260 (200-340)</td>
<td>0.919</td>
</tr>
<tr>
<td>Opening pressure &gt;200 mm H₂O</td>
<td>64.5%</td>
<td>73.3%</td>
<td>0.254</td>
</tr>
<tr>
<td>Cryptococcal culture, log₁₀ CFU/mL</td>
<td>4.6 (3.4-5.3)</td>
<td>4.7 (3.4-5.3)</td>
<td>0.802</td>
</tr>
<tr>
<td>Sterile CSF cryptococcal culture</td>
<td>6.8%</td>
<td>9.5%</td>
<td>0.542</td>
</tr>
<tr>
<td>CSF white-cell count ≥5 cells/mm³</td>
<td>45.7%</td>
<td>44.2%</td>
<td>0.848</td>
</tr>
<tr>
<td>CSF protein, mg/dL</td>
<td>50.0 (20-141.5)</td>
<td>49.5 (20.8-120.0)</td>
<td>0.638</td>
</tr>
<tr>
<td><strong>Follow-up CSF Analysis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 14 CSF Opening pressure &gt;200</td>
<td>43.2%</td>
<td>51.9%</td>
<td>0.393</td>
</tr>
<tr>
<td><strong>Depression at One Month</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CES-D Score</td>
<td>20 (14-28)</td>
<td>18 (11-27)</td>
<td>0.368</td>
</tr>
<tr>
<td>% Depressed (CES-D &gt;16)</td>
<td>64.5%</td>
<td>54.9%</td>
<td>0.286</td>
</tr>
</tbody>
</table>

*P-values from continuous variables calculated with Mann-Whitney U, p-values from categorical variables calculated with Pearson Chi-Square.

CES-D= Center for epidemiologic studies depression scale, IQR= Interquartile Range, ART= Antiretroviral Therapy, CSF= Cerebrospinal Fluid

There is a limited amount of data for the treatment of depression in people living with HIV globally\(^{25,26}\). These interventions are varied, and include therapy and antidepressant medications and showed short-term efficacy but little long-term data\(^{21}\). The interventions are particularly limited in Africa\(^{7}\). In South Africa, Hoare \textit{et al.} conducted a randomized controlled trial of escitalopram in those with HIV-associated depression\(^{7}\). The results of this study were null; however, they only used a starting dose of escitalopram and did not increase the dose or change SSRIs. A recent Cochrane review found some data demonstrating that SSRIs were effective in people with HIV, but none of these studies took place in Africa, and the data were inadequate\(^{5}\). Further work is needed given the large numbers of people from African countries living with HIV and the high prevalence of depression in this population\(^{26-31}\).

Only a few preexisting studies have previously evaluated depression and cryptococcal meningitis. We found one case report of an HIV-positive individual with depression...
associated with cryptococcal meningitis, a case series of HIV-negative individuals with cryptococcal meningitis, and two case reports where HIV-statuses were not revealed. We believe this is the first large study of depression following cryptococcal meningitis diagnosis, and the first randomized, controlled trial of a selective serotonin reuptake inhibitor (SSRI) in those with cryptococcal meningitis.

Limitations
In this study, the participants evaluated were seriously ill with cryptococcal meningitis and AIDS. They were given high-dose sertraline at enrollment but had depression only measured at one and three months, and one month was taken as the baseline measurement. Many individuals died in the first two weeks. Thus, those individuals were not included in one or three-month measurements. CES-D was not measured at baseline, given the prevalence of decreased GCS <15 or more subtle signs of altered mental status, as well as overall poor health, such as headache, nausea, and vomiting. This study may not have generalizability to those without meningitis; however, this is one of the first placebo-controlled randomized control trials of SSRIs in Africans with HIV.

Conclusion
Depression has a high prevalence in survivors of cryptococcal meningitis. We found that sertraline was non-significantly associated with reduced depression in all-comers and meningitis. We found that sertraline was non-significantly associated with reduced depression in all-comers and meningitis; however, this is one of the first placebo-controlled randomized control trials of SSRIs in Africans with HIV.

Data availability
Underlying data
DRYAD: The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis. https://doi.org/10.5061/dryad.n5tb2brt

This project contains the following underlying data:
- Combined_CM_Depression_Database.xlsx (CM patient depression data)

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Acknowledgments
We thank all of the research participants for their willingness to participate in this work. ASTRO-CM Team members include Lillian Tugume, Jane Francis Ndyetukira, Cynthia Ahimbisibwe, Florence Kugonza, Carolyne Namuju, Alisat Sadiq, Henry W Nabeta, James Mwesigye, Paul Kirumira, Michael Okirwoth, Andrew Akampurira, Tony Luggya, Julian Kaboggoza, Eva Laker, Leo Atwine, Davis Munganzi, Bilal Jawed, Matthew Merry, Anna Stadelman, Andrew Flynn, A. Wendy Fujita, Liliane Mukarenema, Bozenna M. Morawski, Kabanda Taseera, and Kirsten Nielsen.

References


Open Peer Review

Current Peer Review Status: ? ?

Version 1

Reviewer Report 27 June 2022

https://doi.org/10.21956/wellcomeopenres.17997.r50426

© 2022 Abas M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Melanie Amna Abas
Health Service and Population Research Department, King's College London, London, UK

This is a clinical trial of Sertraline being used as an adjunctive antifungal agent in people living with HIV in Uganda with cryptococcal meningitis. The authors conducted a secondary analysis to look at the potential benefit of Sertraline on depression.

- I would like the authors to comment on the validity of the CES-D in this Ugandan context.
- Please consider altering language to 'Ugandans' or people from an African country.
- Sertraline was being used as an adjunct antifungal. This should be made clear in the Abstract. I would like the authors to make it very clear if there is confounding by physical health - specifically, was there a greater change in meningitis-related outcomes in the sertraline arm which might account for the reduced depression?
- Sertraline was started and used at a much higher dose than used normally for depression. Please comment on this.

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
No

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Depression, HIV, global mental health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 19 April 2021
https://doi.org/10.21956/wellcomeopenres.17997.r43184

© 2021 Ford N. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nathan Ford
Department HIV and Global Hepatitis Programme, World Health Organization, Geneva, Switzerland

Title
Please specify the study design in the title.

Abstract
“Depression is a risk factor for worse outcomes in persons living with HIV/AIDS...” - What type of outcomes?
This study is not about persons living with HIV/AIDS generally – see comment about the introduction.

Introduction
This study is not about people with chronic illness. It is a specific population. Please rewrite the introduction to focus on the population addressed by this study.

Results
“The median CD4 count was 15 cells/mcL” - Please use standard units: mm$^3$, as used in table 1.

Discussion
Please compare the dosing of Sertraline in this study with usual dosing/frequency as an antidepressant. Also, what is known about time to effectiveness. Given that it generally takes 4-6 weeks to work, how would this be anticipated to affect the outcomes of this trial?

There is a section in the discussion summarizing data on use of data use of antidepressants in
Africans living with HIV. Please expand to summarize what is known about use of antidepressants in people living with HIV in general. Given what is known, is sertraline a rational choice? Also, please summarize other evidence-based interventions for treating depression among people living with HIV, including in Africa (e.g. PMID 32035035).

References

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Yes

If applicable, is the statistical analysis and its interpretation appropriate? Yes

Are all the source data underlying the results available to ensure full reproducibility? Yes

Are the conclusions drawn adequately supported by the results? Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** HIV epidemiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.